Connect with us


Under Armour vs Nike: Which Stock Does The Street Rate As ‘Strong Buy’?

Under Armour vs Nike: Which Stock Does The Street Rate As ‘Strong Buy’?



Apparel and footwear companies have lost billions of dollars due to the pandemic. Even after the easing of lockdown restrictions, it will take a while for these companies to bounce back as tough economic conditions and massive unemployment will have an impact on customers’ discretionary spending.

Amid the current crisis, we will place Nike and Under Armour against each other using the TipRanks’ Stock Comparison tool to see which stock is in a better position to recover based on the Street’s opinion.

Under Armour (UA)

It is not that Under Armour was flourishing before the pandemic. Slowing sales growth, intense competition from Nike, Adidas, and Lululemon in North America, focus on performance footwear and apparel rather than athleisure, and SEC’s investigation into the company’s accounting practices made investors skeptical about Under Armour.

In July, Under Armour disclosed that the company, Kevin Plank (its former CEO and current executive chairman) and David Bergman (current CFO) received Wells notices from the SEC in connection with a previously disclosed probe. The SEC investigation looked into the timing of Under Armour’s sales to check whether the company tried to make them appear healthier than they were. As of September 1, the stock plunged 52% year-to-date.

Meanwhile, Under Armour’s second-quarter revenue declined 40.6% Y/Y to $707.6 million as 80% of the locations where the brand was available were closed through mid-May and strength in e-commerce was not enough to offset the loss of business from physical stores. Apparel, footwear and accessories revenues plunged 42%, 35% and 47%, respectively. North America revenue was down 45% while international business decreased 34%. Under Armour slipped into an adjusted loss per share of $0.31 in the second quarter.  

The company cautioned that though most of the stores have reopened, traffic trends continue to be significantly lower than the prior-year period and this weakness is expected to remain for the remaining of 2020. Under Armour anticipates its revenue to decline by 20% to 25% in the second half of 2020.

In an attempt to rebuild its premium brand positioning, management is reducing its exposure to the off-price channel and is focusing on its direct-to-consumer business.

On August 3, Susquehanna analyst Sam Poser upgraded Under Armour stock to Hold from Sell as he believes that the company is well-positioned for 2021 as the pandemic gave it the needed time to reset its business. Poser raised his price target to $9 from $4.

The analyst feels that the company must “pull back on its presence in the moderate channel at retailers such as Kohl's, Famous Footwear, DSW, SCVL, TJX, ROST, and BURL in order to become the premium brand it once was and to which it aspires to be.” (See UA stock analysis on TipRanks)

Overall, Under Armour stock has a Hold consensus based on the last three months’ ratings, which include 2 Buys, 9 Holds, 1 Sell. The stock might gain 5% over the next 12 months as indicated by the average analyst price target of $9.63.  

Nike (NKE)

The footwear and apparel giant was not spared by COVID-19 as reflected in its fiscal 2020 fourth-quarter (ended May 31) results. However, Nike’s commentary about recovery in the reopened markets and continued momentum in digital business reflects the strength of its business model even in an extremely challenging environment. By the end of June, about 90% of Nike’s owned-stores reopened worldwide.

Nike’s digital sales grew 75% (79% on a currency-neutral basis) in the fiscal fourth quarter and in fact crossed the $1 billion threshold in annual digital revenue in Greater China as well as in the EMEA (Europe, Middle East and Africa) region for the first time. The company continued to experience strong digital momentum even as stores began to reopen.

To support the surge in online shopping amid the pandemic, Nike increased its digital fulfillment capacity by over three times in North America and EMEA in the fiscal fourth quarter.

However, the closure of retail stores had a major impact on the top line and led to a 38% Y/Y decline in the company’s fiscal fourth-quarter revenue of $6.31 billion. The company slipped into a loss per share of $0.51 compared to an EPS of $0.62 in fiscal 2019’s fourth quarter.   

Looking ahead, Nike expects a sequential improvement in its fiscal 2021 quarters as retail markets reopen across the globe. Digital business will continue to be a key priority for Nike as the company aims for 50% digital penetration compared to its previous goal of 30% by 2023. Since February, Nike’s e-commerce app has been downloaded over 8 million times.

Innovation also continues to be a key growth driver for the company. Recent launches include Pegasus 37, Air Max 2090 and VaporMax 2020). (See NKE stock analysis on TipRanks)

On August 19, Susquehanna analyst Sam Poser reiterated his Buy rating for Nike and increased the price target to $150 from $130. The analyst is optimistic that the company will move beyond its Fiscal 2023 revenue target of $50 billion as improving trends, cost savings from planned layoffs, the DTC (direct-to-consumer) focus and forex tailwinds push results higher.

Nike stock had advanced 13% year-to-date as of September 1. However, the average analyst price target of $113.48 is below Poser’s price target and does not indicate any further upside in the coming 12 months. That's despite an optimistic Strong Buy Street consensus.

Nike takes the lead

Under Armour is taking several measures to turnaround its business. But the current crisis poses additional hurdles for the company to rebound. As reflected in the Street’s bullish consensus, Nike is poised to emerge stronger post COVID due to its brand power, innovation, and strong digital penetration.

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment

The post Under Armour vs Nike: Which Stock Does The Street Rate As 'Strong Buy'? appeared first on TipRanks Financial Blog.

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading


Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.



Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 


This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading